Erratum to "Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway".

[This corrects the article DOI: 10.1515/med-2022-0453.].

Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway.

The activation of signaling pathways induced by Toll-like receptor (TLR) has been demonstrated to play essential roles in multiple liver diseases. Toll-interacting protein (Tollip) acts as an endogenous negative modulator of TLR signaling and is implicated in various cardio-metabolic diseases. However, the effect of Tollip in hepatocellular carcinoma (HCC) remains elusive.